Last reviewed · How we verify
NCT04692129: PRONECOVID19
Prone Positioning Short-term Effects on Tissue Oxygen Saturation in Critical COVID-19 Patients
trial in Covid19 in 100 participants. Status unknown.
31 October 2022
Quick facts
| Lead sponsor | Corporacion Parc Tauli |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 29 May 2020 |
| Primary completion | 31 October 2022 |
| Estimated completion | 31 October 2022 |
| Sites | 6 locations across Spain, Brazil, Mexico |
Conditions studied
- Covid19 — all drugs for Covid19 →
- ARDS, Human — all drugs for ARDS, Human →
Sponsor
Corporacion Parc Tauli — full company profile →
Who can join
18 and older, any sex, with Covid19 or ARDS, Human. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to monitor short-term changes in tissue oxygen saturation and local blood flow as results of changing from supine to prone position in ARDS COVID-19 patients
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Performance Assessment of a Commercial Continuous-Wave Near-Infrared Spectroscopy Tissue Oximeter for Suitability for Use in an International, Multi-Center Clinical Trial.
Cortese L, Zanoletti M, Karadeniz U, Pagliazzi M, et al · · 2021 · cited 15× · PMID 34770264 · DOI 10.3390/s21216957
Verify or expand the search:
- PubMed search for NCT04692129
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Corporacion Parc Tauli trials
Trials by the same sponsor.
- NCT07331805 — Conservative Management in Primary Spontaneous Pneumothorax: a Multicenter Randomized Non-inferiority Study · NA · not yet recruiting
- NCT06873360 — Medical Device for Oxaliplatin-Induced Neuropathy in Gastrointestinal Cancer Patients · completed
- NCT06900335 — Functional Connectome in Prader-Willi Syndrome: Neuroimaging and AI to Assess Therapeutic Impact · completed
- NCT06511700 — Implementation of the Intravitreal Injection Administered by Nurses · enrolling by invitation
- NCT07298720 — Assessing Fluid-responsiveness Using Non-invasive Hybrid Diffuse Optics on Peripheral Muscle · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04692129 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Corporacion Parc Tauli
- Last refreshed: 28 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04692129.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing